Literature DB >> 29388013

Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Giuseppe Pelosi1,2,3, Fabrizio Bianchi4, Elisa Dama4, Michele Simbolo5, Andrea Mafficini5, Angelica Sonzogni6, Sara Pilotto7, Sergio Harari8, Mauro Papotti9, Marco Volante10, Gabriella Fontanini11, Luca Mastracci12, Adriana Albini13, Emilio Bria7, Fiorella Calabrese14, Aldo Scarpa5.   

Abstract

Among lung neuroendocrine tumours (Lung-NETs), typical carcinoid (TC) and atypical carcinoid (AC) are considered separate entities as opposed to large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). By means of two-way clustering analysis of previously reported next-generation sequencing data on 148 surgically resected Lung-NETs, six histology-independent clusters (C1 → C6) accounting for 68% of tumours were identified. Low-grade Lung-NETs were likely to evolve into high-grade tumours following two smoke-related paths. Tumour composition of the first path (C5 → C1 → C6) was coherent with the hypothesis of an evolution of TC to LCNEC, even with a conversion of SCLC-featuring tumours to LCNEC. The second path (C4 → C2-C3) had a tumour composition supporting the evolution of AC to SCLC-featuring tumours. The relevant Ki-67 labelling index varied accordingly, with median values being 5%, 9% and 50% in the cluster sequence C5 → C1 → C6, 12% in cluster C4 and 50-60% in cluster C2-C3. This proof-of-concept study suggests an innovative view on the progression of pre-existing TC or AC to high-grade NE carcinomas in most Lung-NET instances.

Entities:  

Keywords:  Cluster analysis; Lung; Neuroendocrine; Transition; Tumours

Mesh:

Year:  2018        PMID: 29388013     DOI: 10.1007/s00428-018-2307-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  44 in total

1.  MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma.

Authors:  L V Debelenko; J I Swalwell; M J Kelley; E Brambilla; P Manickam; G Baibakov; S K Agarwal; A M Spiegel; S J Marx; S C Chandrasekharappa; F S Collins; W D Travis; M R Emmert-Buck
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

2.  Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.

Authors:  Dorian R A Swarts; Sandra M H Claessen; Yvonne M H Jonkers; Robert-Jan van Suylen; Anne-Marie C Dingemans; Wouter W de Herder; Ronald R de Krijger; Egbert F Smit; Frederik B J M Thunnissen; Cornelis A Seldenrijk; Aryan Vink; Aurel Perren; Frans C S Ramaekers; Ernst-Jan M Speel
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

Review 3.  Glioblastoma: pathology, molecular mechanisms and markers.

Authors:  Kenneth Aldape; Gelareh Zadeh; Sheila Mansouri; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

4.  Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

Authors:  Johannes Voortman; Jih-Hsiang Lee; Jonathan Keith Killian; Miia Suuriniemi; Yonghong Wang; Marco Lucchi; William I Smith; Paul Meltzer; Yisong Wang; Giuseppe Giaccone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Authors:  Natasha Rekhtman; Maria C Pietanza; Matthew D Hellmann; Jarushka Naidoo; Arshi Arora; Helen Won; Darragh F Halpenny; Hangjun Wang; Shaozhou K Tian; Anya M Litvak; Paul K Paik; Alexander E Drilon; Nicholas Socci; John T Poirier; Ronglai Shen; Michael F Berger; Andre L Moreira; William D Travis; Charles M Rudin; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2016-03-09       Impact factor: 12.531

6.  Definition of primary and secondary glioblastoma--response.

Authors:  Hiroko Ohgaki; Peter Burger; Paul Kleihues
Journal:  Clin Cancer Res       Date:  2014-02-20       Impact factor: 12.531

7.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

Review 8.  Pathologic Classification of Neuroendocrine Neoplasms.

Authors:  David S Klimstra
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-24       Impact factor: 3.722

9.  CD44 and OTP are strong prognostic markers for pulmonary carcinoids.

Authors:  Dorian R A Swarts; Mieke E R Henfling; Leander Van Neste; Robert-Jan van Suylen; Anne-Marie C Dingemans; Winand N M Dinjens; Annick Haesevoets; Martina Rudelius; Erik Thunnissen; Marco Volante; Wim Van Criekinge; Manon van Engeland; Frans C S Ramaekers; Ernst-Jan M Speel
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

10.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Authors:  Lydia Meder; Katharina König; Luka Ozretić; Anne M Schultheis; Frank Ueckeroth; Carsten P Ade; Kerstin Albus; Diana Boehm; Ursula Rommerscheidt-Fuss; Alexandra Florin; Theresa Buhl; Wolfgang Hartmann; Jürgen Wolf; Sabine Merkelbach-Bruse; Martin Eilers; Sven Perner; Lukas C Heukamp; Reinhard Buettner
Journal:  Int J Cancer       Date:  2015-09-25       Impact factor: 7.396

View more
  22 in total

1.  Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities.

Authors:  Lynnette Fernandez-Cuesta; Matthieu Foll
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 2.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 3.  Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.

Authors:  Melissa Frizziero; Elaine Kilgour; Kathryn L Simpson; Dominic G Rothwell; David A Moore; Kristopher K Frese; Melanie Galvin; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara; Caroline Dive
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

4.  A molecular map of lung neuroendocrine neoplasms.

Authors:  Aurélie A G Gabriel; Emilie Mathian; Lise Mangiante; Catherine Voegele; Vincent Cahais; Akram Ghantous; James D McKay; Nicolas Alcala; Lynnette Fernandez-Cuesta; Matthieu Foll
Journal:  Gigascience       Date:  2020-10-30       Impact factor: 6.524

Review 5.  Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

Authors:  Stefano La Rosa
Journal:  Endocr Pathol       Date:  2021-03-31       Impact factor: 3.943

Review 6.  Lung neuroendocrine tumors: A systematic literature review (Review).

Authors:  Cornel Savu; Alexandru Melinte; Camelia Diaconu; Ovidiu Stiru; Florentina Gherghiceanu; Ștefan Dragoș Octavian Tudorica; Oana Clementina Dumitrașcu; Angelica Bratu; Irina Balescu; Nicolae Bacalbasa
Journal:  Exp Ther Med       Date:  2021-12-28       Impact factor: 2.447

7.  Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept.

Authors:  Giuseppe Pelosi; Federica Massa; Gaia Gatti; Luisella Righi; Marco Volante; Nadia Birocco; Patrick Maisonneuve; Angelica Sonzogni; Sergio Harari; Adriana Albini; Mauro Papotti
Journal:  Clin Pathol       Date:  2019-02-19

8.  Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components.

Authors:  Jean-Luc Raoul; Marie-Françoise Heymann; Frédéric Dumont; Alain Morel; Hélène Senellart; François Bertucci
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

Review 9.  Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy.

Authors:  Helmut Popper; Luka Brcic
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

10.  Carcinoid Tumorlets Co-Existing with Chronic Pulmonary Inflammatory Processes: Imaging Findings and Histological Appearances.

Authors:  Jun Wang; Shuai Ren; Yongkang Liu; Kai Guo; Xiao Chen; Zhongqiu Wang; Rong Chen
Journal:  Med Sci Monit       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.